Selected article for: "adapt change and machine learning"
Author: Mohanty, Eileena; Mohanty, Anima
Title: Role of artificial intelligence in peptide vaccine design against RNA viruses
  • Cord-id: lcvaijbu
  • Document date: 2021_10_23
    • ID: lcvaijbu
    Snippet: RNA viruses have high rate of replication and mutation that help them adapt and change according to their environmental conditions. Many viral mutants are the cause of various severe and lethal diseases. Vaccines, on the other hand have the capacity to protect us from infectious diseases by eliciting antibody or cell-mediated immune responses that are pathogen-specific. While there are a few reviews pertaining to the use of artificial intelligence (AI) for SARS-COV-2 vaccine development, none fo
    Document: RNA viruses have high rate of replication and mutation that help them adapt and change according to their environmental conditions. Many viral mutants are the cause of various severe and lethal diseases. Vaccines, on the other hand have the capacity to protect us from infectious diseases by eliciting antibody or cell-mediated immune responses that are pathogen-specific. While there are a few reviews pertaining to the use of artificial intelligence (AI) for SARS-COV-2 vaccine development, none focus on peptide vaccination for RNA viruses and the important role played by AI in it. Peptide vaccine which is slowly coming to be recognized as a safe and effective vaccination strategy has the capacity to overcome the mutant escape problem which is also being currently faced by SARS-COV-2 vaccines in circulation.Here we review the present scenario of peptide vaccines which are developed using mathematical and computational statistics methods to prevent the spread of disease caused by RNA viruses. We also focus on the importance and current stage of AI and mathematical evolutionary modeling using machine learning tools in the establishment of these new peptide vaccines for the control of viral disease.

    Search related documents:
    Co phrase search for related documents
    • low efficacy and lung cancer: 1, 2, 3, 4, 5
    • low efficacy and machine learning: 1, 2, 3, 4
    • low efficacy and machine model: 1
    • low quality and lung cancer: 1, 2, 3
    • low quality and lymphocytic leukemia: 1
    • low quality and machine learn: 1
    • low quality and machine learning: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
    • low quality and machine model: 1
    • lstm network and machine learning: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24
    • lstm network and machine model: 1, 2, 3
    • lung cancer and lymphocytic leukemia: 1, 2
    • lung cancer and machine learning: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23
    • lung cancer and machine model: 1
    • lung cancer melanoma and machine learning: 1, 2
    • lung cancer melanoma and machine model: 1
    • lymphocytic leukemia and machine learning: 1